CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 90 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.06 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $9,005,000 | -37.7% | 3,031,965 | -3.1% | 1.14% | -67.8% |
| Q2 2020 | $14,462,000 | -13.8% | 3,130,195 | -28.1% | 3.53% | +52.6% |
| Q1 2020 | $16,768,000 | +188.8% | 4,355,416 | +181.3% | 2.31% | +172.1% |
| Q4 2019 | $5,806,000 | -56.4% | 1,548,316 | -38.3% | 0.85% | -47.3% |
| Q3 2019 | $13,322,000 | -9.6% | 2,508,838 | -34.6% | 1.61% | -3.1% |
| Q2 2019 | $14,735,000 | -16.4% | 3,837,181 | +11.0% | 1.67% | -29.3% |
| Q1 2019 | $17,631,000 | +287.8% | 3,457,041 | +46.0% | 2.36% | +289.1% |
| Q4 2018 | $4,547,000 | -28.3% | 2,368,330 | +41.1% | 0.61% | +51.5% |
| Q3 2018 | $6,343,000 | +21.2% | 1,677,944 | 0.0% | 0.40% | +18.7% |
| Q2 2018 | $5,235,000 | +45.2% | 1,677,944 | +11.2% | 0.34% | +43.4% |
| Q1 2018 | $3,605,000 | -0.3% | 1,508,309 | +63.1% | 0.24% | -51.8% |
| Q4 2017 | $3,615,000 | – | 924,648 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |